Circulating microRNAs and Their Role in Multiple Myeloma.
circulating exosomal-miRNAs
circulating miRNAs
miRNAs
multiple myeloma
plasma Cell dyscrasia
Journal
Non-coding RNA
ISSN: 2311-553X
Titre abrégé: Noncoding RNA
Pays: Switzerland
ID NLM: 101652294
Informations de publication
Date de publication:
02 May 2019
02 May 2019
Historique:
received:
13
03
2019
revised:
26
04
2019
accepted:
30
04
2019
entrez:
5
5
2019
pubmed:
6
5
2019
medline:
6
5
2019
Statut:
epublish
Résumé
Multiple myeloma (MM) is a plasma cell dyscrasia characterized by bone marrow infiltration of clonal plasma cells. The recent literature has clearly demonstrated clonal heterogeneity in terms of both the genomic and transcriptomic signature of the tumor. Of note, novel studies have also highlighted the importance of the functional cross-talk between the tumor clone and the surrounding bone marrow milieu, as a relevant player of MM pathogenesis. These findings have certainly enhanced our understanding of the underlying mechanisms supporting MM pathogenesis and disease progression. Within the specific field of small non-coding RNA-research, recent studies have provided evidence for considering microRNAs as a crucial regulator of MM biology and, in this context, circulating microRNAs have been shown to potentially contribute to prognostic stratification of MM patients. The present review will summarize the most recent studies within the specific topic of microRNAs and circulating microRNAs in MM.
Identifiants
pubmed: 31052608
pii: ncrna5020037
doi: 10.3390/ncrna5020037
pmc: PMC6631121
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest. AMR: honoraria from Amgen, Janssen and research support from AstraZeneca; BP: honoraria from Celgene, Janssen and research support from Celgene.
Références
N Engl J Med. 2002 Feb 21;346(8):564-9
pubmed: 11856795
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Genes Dev. 2003 Dec 15;17(24):3011-6
pubmed: 14681208
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
RNA. 2004 Dec;10(12):1957-66
pubmed: 15525708
Nature. 2004 Nov 11;432(7014):235-40
pubmed: 15531877
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
Nature. 2005 Aug 4;436(7051):740-4
pubmed: 15973356
Cancer Res. 2006 Aug 1;66(15):7390-4
pubmed: 16885332
Nat Struct Mol Biol. 2006 Dec;13(12):1097-101
pubmed: 17099701
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Blood. 2007 Aug 15;110(4):1330-3
pubmed: 17496199
N Engl J Med. 2007 Jun 21;356(25):2582-90
pubmed: 17582068
Nat Rev Cancer. 2007 Aug;7(8):585-98
pubmed: 17646864
Blood. 2008 Mar 1;111(5):2516-20
pubmed: 17975015
Cancer Cell. 2008 Feb;13(2):167-80
pubmed: 18242516
Cell. 2008 Mar 7;132(5):875-86
pubmed: 18329372
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12885-90
pubmed: 18728182
RNA. 2009 Jan;15(1):21-32
pubmed: 19029310
Leukemia. 2009 Mar;23(3):435-41
pubmed: 19039321
Blood. 2009 May 28;113(22):5412-7
pubmed: 19179464
Blood. 2009 Jun 25;113(26):6669-80
pubmed: 19401561
Nat Rev Immunol. 2009 Aug;9(8):581-93
pubmed: 19498381
J Clin Oncol. 2009 Sep 1;27(25):4197-203
pubmed: 19636021
Nat Rev Mol Cell Biol. 2010 Apr;11(4):252-63
pubmed: 20216554
Br J Haematol. 2010 May;149(3):311-21
pubmed: 20230410
Nucleic Acids Res. 2010 Nov;38(20):7248-59
pubmed: 20615901
Clin Chem. 2010 Nov;56(11):1733-41
pubmed: 20847327
Semin Hematol. 2011 Jan;48(1):39-45
pubmed: 21232657
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8
pubmed: 21383194
Nat Cell Biol. 2011 Apr;13(4):423-33
pubmed: 21423178
Nat Rev Clin Oncol. 2011 Jun 07;8(8):467-77
pubmed: 21647195
Leukemia. 2012 Feb;26(2):349-55
pubmed: 21836613
Clin Cancer Res. 2011 Oct 15;17(20):6500-9
pubmed: 21856768
Am J Hematol. 2012 Feb;87(2):150-4
pubmed: 22189759
Med Oncol. 2012 Dec;29(4):2402-8
pubmed: 22447484
Lancet Oncol. 2012 Jun;13(6):e249-58
pubmed: 22652233
Leuk Lymphoma. 2013 Jan;54(1):189-91
pubmed: 22712836
Blood Cancer J. 2012 Jan;2(1):e53
pubmed: 22829237
J Biomed Biotechnol. 2012;2012:157496
pubmed: 23093834
Oncotarget. 2012 Oct;3(10):1246-58
pubmed: 23100393
Carcinogenesis. 2013 Feb;34(2):426-35
pubmed: 23104180
Br J Cancer. 2012 Dec 4;107(12):1987-96
pubmed: 23169280
J Cell Physiol. 2013 Jul;228(7):1506-15
pubmed: 23254643
Clin Cancer Res. 2013 Apr 15;19(8):2096-106
pubmed: 23446999
J Clin Invest. 2013 Apr;123(4):1542-55
pubmed: 23454749
Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S125-37
pubmed: 23692413
Cell Cycle. 2013 Dec 1;12(23):3650-62
pubmed: 24091729
Haematologica. 2014 Mar;99(3):511-8
pubmed: 24241494
Nat Commun. 2014;5:2997
pubmed: 24429703
Blood. 2014 Apr 24;123(17):2673-81
pubmed: 24622324
Haematologica. 2014 Jul;99(7):1236-8
pubmed: 24727820
Leukemia. 2014 Sep;28(9):1922-6
pubmed: 24813918
J Cell Physiol. 2014 Dec;229(12):2106-16
pubmed: 24819167
Blood. 2014 Jul 24;124(4):555-66
pubmed: 24928860
Expert Rev Mol Diagn. 2014 Nov;14(8):947-59
pubmed: 25098410
Eur J Haematol. 2015 Apr;94(4):330-5
pubmed: 25135740
Med Oncol. 2014 Oct;31(10):219
pubmed: 25216866
Int J Cancer. 2015 Apr 15;136(8):1835-44
pubmed: 25220540
Blood. 2014 Nov 13;124(20):3110-7
pubmed: 25237203
CA Cancer J Clin. 2014 Nov-Dec;64(6):422-44
pubmed: 25266555
Blood. 2014 Dec 11;124(25):3748-57
pubmed: 25320245
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Immunol Rev. 2015 Jan;263(1):160-72
pubmed: 25510276
Oncotarget. 2015 Jan 30;6(3):1874-83
pubmed: 25593199
Blood. 2015 May 14;125(20):3049-58
pubmed: 25838343
Blood. 2015 May 14;125(20):3059-68
pubmed: 25838346
Leukemia. 2015 Nov;29(11):2173-83
pubmed: 25987254
Tumour Biol. 2015 Dec;36(12):9739-52
pubmed: 26156801
Oncotarget. 2015 Sep 29;6(29):27343-58
pubmed: 26160841
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Stem Cell Res Ther. 2015 Sep 03;6:153
pubmed: 26334526
PLoS One. 2015 Sep 21;10(9):e0137294
pubmed: 26389804
Oncotarget. 2016 Jan 19;7(3):2367-78
pubmed: 26496024
Blood Cancer J. 2016 Jan 15;6:e380
pubmed: 26771806
J Proteomics. 2016 Mar 16;136:89-98
pubmed: 26775013
Sci Rep. 2016 Feb 04;6:20254
pubmed: 26842680
Cancer Discov. 2016 Mar;6(3):235-46
pubmed: 26865249
Biomed Res Int. 2016;2016:6504593
pubmed: 26881223
Oncotarget. 2016 Apr 12;7(15):19589-600
pubmed: 26995755
Oncotarget. 2016 May 24;7(21):30876-91
pubmed: 27129167
Mol Cancer Ther. 2016 Jun;15(6):1364-75
pubmed: 27196750
Cell Discov. 2016 May 31;2:16015
pubmed: 27462462
Funct Integr Genomics. 2017 May;17(2-3):253-262
pubmed: 27647143
Methods Mol Biol. 2016;1464:25-34
pubmed: 27858353
Expert Opin Ther Targets. 2017 Jan;21(1):91-101
pubmed: 27892767
Blood. 2017 Apr 27;129(17):2429-2436
pubmed: 28213378
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Cell Mol Life Sci. 2018 Jan;75(2):193-208
pubmed: 28733901
Haematologica. 2017 Nov;102(11):e456-e459
pubmed: 28775122
J Control Release. 2017 Nov 28;266:100-108
pubmed: 28919558
J Circ Biomark. 2015 Jul 17;4:7
pubmed: 28936243
Oncotarget. 2017 Nov 20;8(63):106527-106537
pubmed: 29290968
Blood Adv. 2017 May 16;1(13):812-823
pubmed: 29296725
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Leukemia. 2018 Sep;32(9):1948-1957
pubmed: 29487387
J Hematol Oncol. 2018 May 8;11(1):63
pubmed: 29739426
Blood. 2018 Sep 6;132(10):1050-1063
pubmed: 29997223
Haematologica. 2019 Feb;104(2):e72-e76
pubmed: 30213829
Mol Cancer Res. 2019 Feb;17(2):337-347
pubmed: 30487244